Search

Syndax Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

17.25 -4.43

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

17.69

Max

18.32

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-6.7M

-49M

Pardavimai

7.9M

73M

Pelnas, tenkantis vienai akcijai

-0.55

Pelno marža

-67.817

Darbuotojai

298

EBITDA

-5.9M

-37M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+103.45% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-02

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-66M

1.6B

Ankstesnė atidarymo kaina

21.68

Ankstesnė uždarymo kaina

17.25

Naujienos nuotaikos

By Acuity

69%

31%

298 / 339 reitingas Healthcare

Syndax Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-15 20:07; UTC

Syndax Pharmaceuticals Inc shares are lower amid a broader market decline following a sharp drop in the NY Empire State Manufacturing Index for September.

2026-09-11 19:36; UTC

News

Syndax Pharmaceuticals is lower today, continuing a downward trend amid heightened market volatility following the August Consumer Price Index release.

2026-09-10 20:03; UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a decline since Wednesday's close, with no specific news identified to explain the movement.

2026-09-08 20:07; UTC

News

Syndax Pharmaceuticals is lower today amid broader market weakness and speculation about a Federal Reserve interest rate hike following strong labor data.

2026-09-02 20:08; UTC

Syndax Pharmaceuticals Inc shares are higher today, despite earlier pulling back from a session high amid broader market volatility and slower job growth indicators.

2026-09-01 20:09; UTC

News

Syndax Pharmaceuticals shares are higher as the company announces participation in two investor conferences to boost visibility for its cancer therapies.

2026-08-25 19:26; UTC

Syndax Pharmaceuticals Inc shares are higher today, maintaining gains since Monday. The stock remains above the 20-day moving average amid declining yields.

2026-08-24 19:51; UTC

Syndax Pharmaceuticals Inc is trading lower, breaking a trend of higher closes. Broader market sentiment is impacted by concerns over U.S.-Iran relations and oil supply disruptions.

2026-08-21 19:21; UTC

Syndax Pharmaceuticals shares are lower today, breaking a trend of higher closes since Thursday. The broader market faces volatility amid rising crude oil prices.

2026-08-20 20:02; UTC

Correlated Moves

Syndax trades lower amid decline in SPDR S&P Biotech ETF.

2026-08-19 19:27; UTC

Correlated Moves

SNDX higher today, supported by strong biotechnology sector performance.

2026-08-18 19:56; UTC

Syndax Pharmaceuticals is trading higher today, despite pulling back from earlier session gains. The stock remains positioned near the lower end of its one-month range.

2026-08-17 19:36; UTC

Correlated Moves

Shares higher today as iShares Biotechnology ETF also gains.

2026-08-14 19:26; UTC

Syndax Pharmaceuticals Inc shares are trading higher during Friday's session, reflecting positive market sentiment despite broader concerns over a decline in U.S. retail sales.

2026-08-12 19:31; UTC

Syndax Pharmaceuticals shares are lower, reversing a recent trend of gains. No specific news was identified to explain the decline.

2026-08-11 19:26; UTC

News

SNDX trades lower after JPMorgan cuts price target to $40.00.

2026-08-10 19:36; UTC

Syndax Pharmaceuticals shares are lower amid broader market volatility and rising oil prices due to geopolitical tensions in the Strait of Hormuz.

2026-08-06 19:36; UTC

News

Syndax Pharmaceuticals is lower today, facing volatility amid broader market conditions and recent economic data impacting Federal Reserve policy.

2026-08-05 20:02; UTC

News
Social Media

Syndax Pharmaceuticals shares rise after H.C. Wainwright maintains Buy rating and lowers price target to $38, citing strong revenue growth of $73 million.

2026-08-04 23:11; UTC

News

Syndax Pharmaceuticals shares are lower in after-market hours following a second-quarter earnings miss, reporting a net loss of $49.4 million and revenue of $72.8 million.

2026-08-03 19:16; UTC

Correlated Moves

Syndax Pharmaceuticals Inc shares are higher amid a broader market rally. The stock remains below its 20-day moving average and near the lower end of its one-month range.

2026-07-31 20:06; UTC

Correlated Moves

Syndax Pharmaceuticals Inc shares declined after first-quarter results showed lower performance. Broader market pressures from rising yields and oil prices contributed to the decline.

2026-07-30 17:06; UTC

Syndax Pharmaceuticals shares are higher as the broader market recovers, with the S&P 500 advancing following recent volatility in U.S. Treasury yields.

2026-07-29 19:56; UTC

Macro Event

Syndax Pharmaceuticals Inc shares are lower, continuing a trend with six consecutive daily declines amid broader market concerns over rising crude oil prices.

2026-07-28 20:51; UTC

Syndax Pharmaceuticals Inc is trading lower in after-market hours, continuing a six-session decline amid market focus on the Federal Reserve's interest rate decision.

2026-07-27 20:06; UTC

Syndax Pharmaceuticals shares are lower as the broader market declines amid falling oil prices, impacting Treasury yields and investor sentiment.

2026-07-24 19:52; UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a downward trend over the past few days amid broader market pressures.

2026-07-22 19:06; UTC

Syndax Pharmaceuticals Inc shares are lower today with no specific news identified. Broader market sentiment is impacted by rising crude oil prices and geopolitical tensions.

Akcijų palyginimas

Kainos pokytis

Syndax Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

103.45% į viršų

12 mėnesių prognozė

Vidutinis 37.333 USD  103.45%

Aukščiausias 57 USD

Žemiausias 26 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Syndax Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

10

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

298 / 339 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
help-icon Live chat